Table 1.
A-285222 treatment does not affect plasma cytokine levels in diabetic NFAT-luc mice.
| Cytokine (pg/mL) |
Control (N = 10) |
STZ (N = 13) |
STZ + A-285222 (N = 8) |
|---|---|---|---|
| IL-10 | 22.0 ± 3.6 | 28.1 ± 7.0 | 29.4 ± 21.1 |
| TNF-α | 0.7 ± 0.3 | 0.6 ± 0.5 | 0.2 ± 0.5 |
| IFN-γ | 1.3 ± 1.3 | 1.2 ± 0.5 | 1.4 ± 0.8 |
| IL-12p70 | 3.9 ± 5.5 | 8.2 ± 9.0 | 32.7 ± 56.2 |
| IL-1β | 1.0 ± 0.4 | 1.2 ± 0.5 | 1.1 ± 0.8 |
| IL-6 | 13.3 ± 5.7 | 16.6 ± 5.8 | 25.0 ± 22.4 |
| KC | 51.4 ± 27.5 | 56.5 ± 17.7 | 64.1 ± 53.6 |
Data expressed as mean ± SD. Plasma cytokine levels (pg/mL) in control and STZ-treated NFAT-luc mice that had been treated with the NFAT inhibitor A-285222 (0.15 mg/kg/day) or saline, measured 2 weeks after the first STZ/vehicle injection. One-way ANOVA revealed no significant differences between groups. Interleukin- (IL-) 10, tumor necrosis factor- (TNF-) α, interferon- (IFN-) γ, IL-12p70, IL-1β, IL-6, and keratinocyte chemoattractant (KC) were measured using multiplex technology.